Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Anandamide ((5Z,8Z,11Z,14Z)-N-(2-Hydroxyethyl)icosa-5,8,11,14-tetraenamide) 是一种免疫调节剂,通过大麻素受体 CB1 和 CB2 起作用,还通过中枢神经系统中的其他靶点起作用,如 GPR18/GPR55。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 248 | 现货 | ||
2 mg | ¥ 368 | 现货 | ||
5 mg | ¥ 583 | 现货 | ||
10 mg | ¥ 1,150 | 现货 | ||
25 mg | ¥ 2,250 | 现货 | ||
50 mg | ¥ 3,380 | 现货 | ||
100 mg | ¥ 4,920 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 668 | 现货 |
产品描述 | Anandamide ((5Z,8Z,11Z,14Z)-N-(2-Hydroxyethyl)icosa-5,8,11,14-tetraenamide), an immune modulator, acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18/GPR55) in the central nervous system. |
体外活性 | Anandamide, acting via CB2 receptors, alleviates lipopolysaccharide (LPS)-induced neuroinflammation in rat primary microglial cultures. Endocannabinoids, especially Anandamide (AEA), can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55 [1]. |
体内活性 | Anandamide is an endocannabinoid binding both CB1R and CB2R. To evaluate the impact of CBR activation on whole-body glucose homeostasis, glucose tolerance is assessed after a single intraperitoneal Anandamide injection (10 mg/kg). The increase in glycemia in response to glucose ingestion is considerably smaller in mice treated with Anandamide compared with control. It is associated with an improvement of glucose tolerance as illustrated by the AUC0-2h calculations[2]. |
别名 | 花生四烯酸乙醇胺, (5Z,8Z,11Z,14Z)-N-(2-Hydroxyethyl)icosa-5,8,11,14-tetraenamide |
分子量 | 347.53 |
分子式 | C22H37NO2 |
CAS No. | 94421-68-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 10 mg/mL (28.77 mM)
DMSO: 250 mg/mL (719.36 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.8774 mL | 14.3872 mL | 28.7745 mL | 71.9362 mL |
5 mM | 0.5755 mL | 2.8774 mL | 5.7549 mL | 14.3872 mL | |
10 mM | 0.2877 mL | 1.4387 mL | 2.8774 mL | 7.1936 mL | |
20 mM | 0.1439 mL | 0.7194 mL | 1.4387 mL | 3.5968 mL | |
DMSO | 50 mM | 0.0575 mL | 0.2877 mL | 0.5755 mL | 1.4387 mL |
100 mM | 0.0288 mL | 0.1439 mL | 0.2877 mL | 0.7194 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Anandamide 94421-68-8 GPCR/G Protein Metabolism Endogenous Metabolite Cannabinoid Receptor Transient receptor potential channels Inhibitor inhibit Alzheimer’s disease Candida albicans anti-fungal anti-adhesive cervical epithelial cells 花生四烯酸乙醇胺 G protein-coupled receptor 55 Streptozotocin (5Z,8Z,11Z,14Z)-N-(2-Hydroxyethyl)icosa-5,8,11,14-tetraenamide hVSMC N-(2-Hydroxyethyl)icosa-5,8,11,14-tetraenamide HeLa cells GPR55 TRP Channel endocannabinoid Peroxisome proliferator-activated receptors Fungal PPAR Tau Protein inhibitor